Back to Trials
NCT07324031NARecruiting

Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study

AtaCor Medical, Inc.

Start Date

7/2/2026

Completion Date

12/31/2028

Summary

The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System. The objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.

Detailed Description

The primary safety endpoint is Freedom from Major Adverse Device Effects (MADEs) through 6 months. The primary effectiveness endpoint is Defibrillation Performance: Successful induced ventricular arrhythmia (IVA) test in the final system configuration. Up to 40 Investigational Sites Worldwide will participate with up to 280 subjects enrolled in the study. At least 50% of subjects will be enrolled at sites in the United States. Subjects meeting indications for ICD therapy who do not require permanent bradycardia pacing will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to an EV-ICD Pulse Generator positioned in a left pectoral or left lateral location. The Parasternal EV-ICD System will be tested to verify appropriate sensing and defibrillation. Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to be ongoing for a minimum of 2.5 years from the date of first enrollment. Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 6-month visit.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: 1. At least 18 years old 2. Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines or ESC guidelines Exclusion Criteria: 1. Patients who cannot read or write 2. Expected survival \< 1 year 3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period 4. Participation in any concurrent clinical study without prior approval from the Sponsor 5. Inability or unwillingness to provide informed consent to participate in the study 6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit 7. Circumstances that may prevent data collection or completion of specified follow-up visits 8. Allergies to any device materials listed in the Instructions for Use (IFU) 9. Contraindication for temporary suspension of oral/systemic anticoagulation 10. Known history of lung disease with FEV1 \< 1.0 Liter Device Related: 11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator 12. Implanted with a subcutaneous ICD lead, subcutaneous coils/arrays, epicardial patches or epicardial pace/sense leads 13. Any known need for MRI prior to approval of MRI conditional labeling Anatomy Related: 14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure 15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead 16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type 17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis) 18. History of thoracic radiation therapy or other medical treatments/conditions which may complicate the Parasternal EV-ICD System implant procedure 19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax 20. Surgically corrected congenital heart disease (not including catheter-based procedures) Cardiac Related: 21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy 22. Decompensated heart failure 23. Currently on inotropic therapy 24. Known history of pericardial disease, pericarditis or mediastinitis 25. Risk factors associated with defibrillation testing: * Severe aortic stenosis * Current Intracardiac LA or LV thrombus * Severe proximal three-vessel or left main coronary artery disease without revascularization * Hemodynamic instability * Unstable angina * Recent stroke or transient ischemic attack (within the last 3 months) * Known inadequate external defibrillation * LVEF \< 20% (most recent assessment; must be within 180 days of consent) * LVEDD \>70 mm (most recent assessment; must be within 180 days of consent)

Interventions

DEVICE

Atala™ lead and EV-ICD Pulse Generator

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Ventricular ArrythmiaVentricular FibrillationVentricular Tachycardia

Locations

Honor Health

Scottsdale, Arizona 85258

United States

St. Bernards Heart and Vascular

Jonesboro, Arkansas 72401

United States

UC San Diego Health

La Jolla, California 92037

United States

Providence Medical Foundation

Orange, California 92868

United States

Cedars-Sinai Medical Center

Santa Monica, California 90404

United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia 20010

United States

Mount Sinai Medical Center of Florida

Miami Beach, Florida 33140

United States

AdventHealth

Orlando, Florida 32803

United States

Emory University

Atlanta, Georgia 30308

United States

Endeavor Health

Glenview, Illinois 60026

United States

Baptist Health

Lexington, Kentucky 40503

United States

John Hopkins Medical

Baltimore, Maryland 21287

United States

Mayo Clinic

Rochester, Minnesota 55902

United States

Cooper Health

Voorhees Township, New Jersey 08043

United States

Northwell Health

Manhasset, New York 11030

United States

Advocate/Atrium Health - Sanger Heart and Vascular

Charlotte, North Carolina 28204

United States

East Carolina Heart Institute at ECU

Greenville, North Carolina 27834

United States

North Carolina Heart and Vascular

Raleigh, North Carolina 27607

United States

Novant Health

Winston-Salem, North Carolina 27103

United States

Advocate/Atrium Health - Wake Forest Baptist

Winston-Salem, North Carolina 27157

United States

The Carl & Edyth Lindner Center for Research and Education at The Christ Hospital

Cincinnati, Ohio 45219

United States

University Hospitals of Cleveland

Cleveland, Ohio 44106

United States

OhioHealth Research Institute

Columbus, Ohio 43228

United States

Penn State Health Milton S. Hershey Medical Center

Hershey, Pennsylvania 17033

United States

University of Pennsylvania

Philadelphia, Pennsylvania 19104

United States

Medical University of South Carolina

Charleston, South Carolina 29425

United States

Texas Cardiac Arrhythmia Research

Austin, Texas 78705

United States

Haga Hospital

The Hague, AA 2545

Netherlands

Isala Hospital

Zwolle, AB 8025

Netherlands

Amsterdam University Medical Center

Amsterdam, AZ 1105

Netherlands

St. Antonius Hospital

Nieuwegein, CM 3435

Netherlands

Erasmus Medical Center

Rotterdam, Gelderland 3015

Netherlands

Maastricht University Medical Center

Maastricht, HX 6229

Netherlands

Medical Spectrum Twente

Enschede, KZ 7512

Netherlands

University Medical Center Groningen

Groningen, RB 9700

Netherlands